Reported about 10 hours ago
AbbVie Inc. has successfully extended the patent for its drug Rinvoq until 2037, following a settlement with generic manufacturers. This extension delays the entry of generics by about four years, ensuring continued sales of Rinvoq, which generated nearly $6 billion in revenue in 2024. The company is focused on expanding its immunology portfolio and leveraging AI in drug development, while also enhancing its manufacturing capabilities.
Source: YAHOO